On June 5, 2018 Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to improve protein therapies for unmet patient needs, reported that Eef Schimmelpennink, Chief Executive Officer, will be presenting a corporate overview at the JMP Securities Life Sciences Conference, taking place June 19-20 at The St. Regis New York hotel in New York City (Press release, Pfenex, JUN 5, 2019, View Source [SID1234538432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Date: Wednesday, June 19, 2019
Time: 12:30pm Eastern Time

Interested parties can access the live audio webcast and archive from the Investors Section of Pfenex’s website at www.pfenex.com.